| Variables |
hs-cTnTlow group (n:205) |
hs-cTnThigh group (n:206) |
P |
| Baseline characteristics |
|
|
|
| Age, years |
59.1 ± 9.6 |
64.3 ± 9.5 |
<0.001 |
| Gender (Male) |
120 (58.3%) |
127 (62.0%) |
0.253 |
| Body mass index, kg/m2 |
27.5 ± 3.7 |
27.6 ± 3.6 |
0.864 |
| Systolic blood pressure, mmHg |
124.5 ± 17.2 |
127.4 ± 16.2 |
0.082 |
| Diastolic blood pressure, mmHg |
76.3 ± 10.0 |
77.8 ± 9.8 |
0.137 |
| Heart Rate, beat/minute |
76.9 ± 10.0 |
75.2 ± 9.2 |
0.082 |
| Hypertension, n (%) |
85 (41.3%) |
110 (53.7%) |
0.008 |
| Diabetes mellitus, n (%) |
32 (15.5%) |
122 (59.5%) |
<0.001 |
| Hyperlipidemia, n (%) |
132 (64.1%) |
117 (57.1%) |
0.088 |
| Smoking, n (%) |
73 (35.4%) |
62 (35.2%) |
0.155 |
| Laboratory findings |
|
|
|
| Total Cholesterol, mg/dl |
191.4 ± 43.8 |
182.0 ± 44.2 |
0.033 |
| Triglyceride, mg/dl median (25th-75th) |
138 (113-227.5) |
147 (97.5-210) |
0.353 |
| HDL-C, mg/dl |
42.8 ± 18.8 |
40.3 ± 9.5 |
0.078 |
| LDL-C, mg/dl |
128.3 ± 38.7 |
117.2 ± 38.5 |
0.016 |
| Fasting glucose, mg/dl |
119.2 ± 57.5 |
142.7 ± 74.9 |
<0.001 |
| CK-MB, ng/mL |
2.6 ± 1.2 |
2.9 ± 1.3 |
0.321 |
| HsCRP, mg/dl median (25th-75th) |
0.82 (0.54-1.12) |
1.10 (0.73-1.60) |
<0.001 |
| Creatinine, mg/dl |
0.81 ± 0.20 |
0.98 ± 0.26 |
<0.001 |
| Hemoglobin, mg/dL |
13.9 ± 3.4 |
14.1 ± 3.6 |
0.334 |
| Ejection Fraction, % |
64.4 ± 4.6 |
63.6 ± 4.5 |
0.104 |
| SYNTAX Score median (25th-75th) |
6.0 (4.5-10) |
17 (10.8-25.5) |
<0.001 |
| Previous medications, n (%) |
|
|
|
| ACE-I |
35 (17.0%) |
46 (22.4%) |
0.103 |
| Angiotensin receptor blocker |
51 (24.8%) |
54 (26.3%) |
0.399 |
| Statin |
86 (41.7%) |
84 (40.9%) |
0.543 |
| Beta blocker |
16 (7.7%) |
15 (7.3%) |
0.632 |
| Aspirin |
59 (28.6%) |
65 (31.7%) |
0.356 |
| Oral anti-diabetic |
15 (7.3%) |
105 (51.2%) |
<0.001 |
Hs-cTnT; high-sensitivety cardiac troponin T, HDL-C; high density lipoprotein
cholesterol, LDL-C; low density lipoprotein cholesterol, HsCRP; high sensitive
C reactive protein, SYNTAX; the Synergy between Percutaneous Coronary
Intervention with Taxus and Cardiac Surgery, ACE-I; angiotensin converting
enzyme inhibitor.
Data are n (%) for categorical variables, means ± SD for continuous variables, or
median (25 and 75% interquartiles) for non–normally distributed variables. |
